

PL 1117806

# THE UNITED STATES OF AMERICA

**TO ALL TO WHOM THESE PRESENTS SHALL COME:**

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

January 22, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/477,453


FILING DATE: June 10, 2003

RELATED PCT APPLICATION NUMBER: PCT/US03/36292

REC'D 26 JAN 2004

WIPO PCT

By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS



  
M. K. HAWKINS  
Certifying Officer

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

*[Faint, illegible handwritten text]*

PTO/SB/16 (08-03)

Approved for use through 4/30/2003. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
to a collection of information unless it displays a valid OMB control number.


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# PROVISIONAL APPLICATION FOR PATENT COVER SHEET

**This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).**

**Express Mail Label No. EV 342609100 US**

17513 U.S. PTO  
60/47745  
06/10/03

INVENTOR(S)			
Given Name (first and middle [if any])		Family Name or Surname	Residence (City and either State or Foreign Country)
Gaetano T. Robert M.		Montellione Krug	Highland Park, New Jersey Austin, Texas
Additional Inventors are being named on the _____ separately numbered sheets attached hereto			
TITLE OF THE INVENTION (500 characters max)			
PROCESS FOR DESIGNING INHIBITORS OF THE LIFE CYCLE OF INFLUENZA A VIRUS TARGETED TO THE VIRAL NON-STRUCTURAL PROTEIN 1			
Direct all correspondence to: CORRESPONDENCE ADDRESS			
<input checked="" type="checkbox"/> Customer Number		<input type="text"/>	 000530 Customer Number Bar Code
OR			
<input type="checkbox"/> Firm or Individual Name			
Address			
City		State	Zip
Country		Telephone	Fax
ENCLOSED APPLICATION PARTS (check all that apply)			
<input checked="" type="checkbox"/> Specification Number of Pages		<input type="text" value="3"/>	<input type="checkbox"/> CD(s), Number <input type="text"/>
<input type="checkbox"/> Drawing(s) Number of Sheets		<input type="text"/>	<input type="checkbox"/> Other: <input type="text"/>
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76			
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT			
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		FILING FEE AMOUNT (\$)	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees.			
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:		<input type="text" value="12-1095"/>	<input type="text" value="80.00"/>
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.			
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.			
<input type="checkbox"/> No		<input checked="" type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:	
		NIH - GM47014; AI1772	

**Respectfully submitted,**

**SIGNATURE**

**TYPED OR**

PRINTED NAME

TELEPHONE

Herold P Norton

Gerard P. Norton

**(908) 518-6384**

Date June 10, 2003

**REGISTRATION NO.**

(if appropriate)

**Docket Number:**

**36.621**

OCIRS 3.8-081

**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

**Application Data Sheet**

**Application Information**

Application Type::	Provisional
Subject Matter::	Utility
Suggested Group Art Unit::	N/A
CD-ROM or CD-R?::	None
Sequence submission?::	None
Computer Readable Form (CRF)?::	No
Title::	PROCESS FOR DESIGNING INHIBITORS OF THE LIFE CYCLE OF INFLUENZA A VIRUS TARGETED TO THE VIRAL NON- STRUCTURAL PROTEIN 1
Attorney Docket Number::	OCIRS 3.8-081
Request for Early Publication?::	No
Request for Non-Publication?::	No
Total Drawing Sheets::	0
Small Entity?::	Yes
Petition included?::	No
Licensed US Govt. Agency::	NIH
Contract or Grant Numbers::	GM47014; AI11772
Secrecy Order in Parent Appl.?::	No

**Applicant Information**

Applicant Authority Type::	Inventor
Primary Citizenship Country::	US
Status::	Full Capacity
Given Name::	Gaetano
Middle Name::	T.
Family Name::	Montellione
City of Residence::	Highland Park
State or Province of Residence::	NJ

[illegible]

### Correspondence Information

### Representative Information

### Assignee Information

Page # 2

Initial 06/10/03

08903 08903 08903

Postal or Zip Code of mailing address:: 08903

PROCESS FOR DESIGNING INHIBITORS  
OF THE LIFE CYCLE OF INFLUENZA A VIRUS  
TARGETED TO THE VIRAL NON-STRUCTURAL PROTEIN 1

The Multiple Functions Of The NS1 Protein Of Influenza A Virus (NS1A Protein) In The  
Intracellular War Between The Virus And Human Cells

The intracellular war between influenza A virus and human cells is comprised of several battles, and the viral NS1A protein plays a major role in many of these battles. The first battle: infection of human cells by influenza A virus activates the interferon (IFN)-independent transcription of antiviral genes mediated by activated interferon regulatory factor-3 (IRF-3) transcription factor. The NS1A protein counters this cellular antiviral response at the post-transcriptional level by binding cellular proteins required for the 3' end processing of cellular pre-mRNAs. Mature antiviral mRNAs are not made unless the virus encodes a NS1A protein with a mutated effector domain binding site for one of these cellular factors (CPSF). This mutation also affects a second cellular antiviral response; IFN-beta mRNA is produced earlier and in larger amounts, because post-transcriptional processing of cellular pre-mRNAs is not inhibited throughout infection. In addition, the NS1A protein is localized in the cytoplasm, indicating that CPSF binding mediates nuclear import/retention of the NS1A protein. Another sequence in the NS1A effector domain, the nuclear export signal (NES, amino acids 137-146) plays an important role, because a recombinant virus encoding a NS1A protein with a mutated NES is substantially attenuated. The N-terminal RNA-binding domain, which binds double-stranded RNA (dsRNA) with low affinity, plays a different role, as demonstrated using recombinant viruses that encode NS1A proteins whose only defect is in RNA-binding: PKR, expressed constitutively in the absence of IFN, is activated, eIF2-

alpha is phosphorylated, and viral protein synthesis is inhibited. After its activation, PKR is degraded.

# The RNA Binding Domain Of The NS1 Protein Of Influenza A Virus: Identification Of One Of Its Functions During Virus Infection

The NS1 protein of influenza A virus (NS1A protein) plays a major role in the intracellular war between the virus and human cells. Functions of the effector domain of the NS1A protein, which comprises the C-terminal two-thirds of the protein, have been elucidated. In contrast, the function of the N-terminal RNA-binding domain of the NS1A protein, which binds dsRNA with low affinity, has not been established. For example, it does not sequester dsRNA to prevent the activation of either IRF-3 or NF-kappaB. Here we determine whether dsRNA binding by this domain prevents activation of PKR during infection. Activated PKR phosphorylates the translation initiation factor eIF2 $\alpha$ , resulting in the inhibition of protein synthesis and virus replication. Substantial amounts of PKR, which can be activated by dsRNA or by specific proteins, are expressed constitutively in the absence of interferon. Previous results from others indicated that the amino acids of the NS1A protein that participate in the inhibition of PKR do not include those that are required for RNA binding. We generated recombinant A/Udorn/72 viruses that encode NS1A proteins whose only defect is in RNA binding. Because the R at position 38 (R38) and K41 are the only amino acids that are required solely for RNA binding, we substituted A for either one or both of these amino acids. The three mutant viruses are highly attenuated: the R38 and K41 mutant viruses form pin-point plaques, and the double mutant (R38/K41) does not form visible plaques. During high multiplicity infection of A549 cells with any of these mutant viruses, PKR is activated, eIF2 $\alpha$  is phosphorylated, and viral protein synthesis is inhibited. Surprisingly, after its activation, PKR is degraded. The R38/K41 double mutant is most effective in inducing PKR

activation. We conclude that one of the intracellular functions of the RNA-binding domain of the NS1A protein is to prevent the activation of PKR by binding dsRNA.

435169\_1.DOC